Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
EDITOR In our review of 608 randomised controlled trials, we found that 290 of
the trials (47.7%) explicitly mentioned that they applied the
principle of intention to treat analysis. The reporting of this issue
increased slightly between 1993 and 1995 (although the increase was not
significant). Trials with a greater number of participants and those
funded by the pharmaceutical industry were more likely to report the
application of the intention to treat principle (table). In the
multivariable logistic regression analysis, when we controlled for the
general characteristics previously described, we found that trials with
survival of patients as the principal outcome were more frequently
reported to follow the intention to treat principle. In addition, those
randomised controlled trials that gave no information about sample size
were less likely to report the use of this principle (table).
Randomised controlled trials not reporting the number of withdrawals or
losses to follow up and those not reporting information about
compliance with treatment were also less likely to report the intention
to treat principle, although these results were not
significant.
In their survey of all randomised controlled trials
published in 1997 in four major medical journals, Hollis and Campbell found that only 48% of the reports explicitly mentioned intention to
treat analysis.1 In a considerable proportion it was
insufficiently described and sometimes inadequately applied. Their
results are confirmed by our assessment of all randomised controlled
trials published between 1993 and 1995 in the same four
journals.2 In addition to our assessment of ethical
issues, we calculated the proportion of randomised controlled trials
reporting intention to treat analysis in accordance with different
descriptive and methodological characteristics.
Our data support the relation between a higher methodological
quality of the trials and the reporting of the intention to treat
analysis. Our results reinforce the conclusions of Hollis and Campbell
that the application of this principle still needs to improve because
it seems that there has been no improvement between 1993 and
1997.1 A joint effort of editors and researchers is needed
to meet the CONSORT guidelines3 and the authors' recommendations favouring intention to treat analysis.1 A
better quality of reporting will help readers to assess the design,
conduct, and analysis of randomised controlled trials more critically.
Miguel Ruiz-Canela
Department of Biomedical Humanities and Department of
Epidemiology and Public Health, School of Medicine, University of
Navarra, E 31080 Pamplona, Spain mcanela{at}unav.es
Miguel Angel Martínez-González
Jokin de Irala-Estévez
Department of Epidemiology and Public Health, School of
Medicine, University of Navarra
| 1. |
Hollis S, Campbell F.
What is meant by intention to treat analysis? Survey of published randomised controlled trials.
BMJ
1999;
319:
670-674 |
| 2. |
Ruiz-Canela M, Martínez-González MA, Gómez Gracia E, Fernández-Crehuet Navajas J.
Informed consent and approval by institutional review board in published clinical trials.
N Engl J Med
1999;
340:
1114-1115 |
| 3. | Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276: 637-639[CrossRef][Medline]. |